SOUTH SAN FRANCISCO, Calif. — August 7, 2025 — Leads & Copy — Pliant Therapeutics, Inc. (Nasdaq: PLRX) announced a corporate update and reported its second quarter 2025 financial results, focusing on the BEACON-IPF closure and workforce realignment. Despite discontinuing bexotegrast development in idiopathic pulmonary fibrosis (IPF) after unfavorable risk-benefit findings, the company is advancing its oncology program, with Phase 1 trial data of PLN-101095 expected by year-end.
The company’s restructuring, announced in May, was largely completed by the end of Q2. Research and development expenses decreased to $32.2 million, and general and administrative expenses fell to $13.4 million. Net loss was $43.3 million, with cash, cash equivalents, and short-term investments at $264.4 million as of June 30, 2025.
Pliant is also progressing with a Phase 1 study of PLN-101325 for muscular dystrophies and continues preclinical research on tissue-specific drug delivery.
Christopher Keenan, Vice President, Investor Relations and Corporate Communications, can be reached at ir@pliantrx.com
Source: Pliant Therapeutics, Inc.
